12-month Results of the ILLUMENATE European Randomized Clinical Trial to be Presented at the Amputation Prevention Symposium
July 20 2016 - 9:00AM
The Spectranetics Corporation (NASDAQ:SPNC) today announced that
Professor Marianne Brodmann of Medical University Graz, Austria,
will present the final 12-month results of the Stellarex
Drug-coated Balloon’s ILLUMENATE European Randomized Clinical Trial
at the Amputation Prevention Symposium (AMP) in Chicago, Illinois,
on August 10, 2016. The presentation will begin at 4:40 pm CDT.
The ILLUMENATE European Randomized Clinical Trial enrolled more
than 300 patients suffering from peripheral arterial disease. The
study results will be available sooner than previously anticipated
and will be presented for the first time at AMP. The data will also
be shared at the Vascular Interventional Advances (VIVA) conference
in Las Vegas, Nevada, in September.
About the Stellarex DCB Platform
The Stellarex DCB platform is designed to treat peripheral
arterial disease. The Stellarex DCB uses EnduraCoat™ technology, a
durable, uniform coating designed to prevent drug loss during
transit and facilitate controlled, efficient drug delivery to the
treatment site. The Stellarex DCB platform received CE mark to be
marketed in the European Union in December 2014. It is not for sale
in the United States.
About Spectranetics
The Spectranetics Corporation develops, manufactures, markets
and distributes medical devices used in minimally invasive
procedures within the cardiovascular system. The Company's products
are available in over 65 countries and are used to treat arterial
blockages in the heart and legs and in the removal of pacemaker and
defibrillator leads.
The Company's Vascular Intervention (VI) products include a
range of laser catheters for ablation of blockages in arteries
above and below the knee, the AngioSculpt scoring balloon used in
both peripheral and coronary procedures, and the Stellarex
drug-coated balloon peripheral angioplasty platform, which received
European CE mark approval in December 2014. The Company also
markets support catheters to facilitate crossing of peripheral and
coronary arterial blockages, and retrograde access and guidewire
retrieval devices used in the treatment of peripheral arterial
blockages, including chronic total occlusions. The Company markets
aspiration and cardiac laser catheters to treat blockages in the
heart.
The Lead Management (LM) product line includes excimer laser
sheaths, dilator sheaths, mechanical sheaths and accessories for
the removal of pacemaker and defibrillator cardiac leads.
For more information, visit www.spectranetics.com.
Investor Relations Contacts
Zach Stassen
Sr. Director of Finance
zach.stassen@spnc.com
(719) 447-2292
Michaella Gallina
Director of Investor Relations
michaella.gallina@spnc.com
(719) 447-2417
The Spectranetics Corp. (MM) (NASDAQ:SPNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
The Spectranetics Corp. (MM) (NASDAQ:SPNC)
Historical Stock Chart
From Apr 2023 to Apr 2024